Skip to main content

Fylnetra FDA Approval History

Last updated by Judith Stewart, BPharm on May 31, 2022.

FDA Approved: Yes (First approved May 26, 2022)
Brand name: Fylnetra
Generic name: pegfilgrastim-pbbk
Dosage form: Injection
Company: Amneal Pharmaceuticals LLC
Treatment for: Neutropenia Associated with Chemotherapy

Fylnetra (pegfilgrastim-pbbk) is a leukocyte growth factor biosimilar to Neulasta (pegfilgrastim) used to reduce the incidence of neutropenia in patients undergoing chemotherapy.

Development timeline for Fylnetra

May 27, 2022Approval FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.